Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Quebec Clinical Research Organization in Cancer
Novartis
Hoffmann-La Roche
Information provided by (Responsible Party):
Sarit Assouline, Jewish General Hospital
ClinicalTrials.gov Identifier:
NCT01238692
First received: November 10, 2010
Last updated: September 20, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)